Background Paclitaxel (PTX) occupies a considerable status in the chemotherapies of
breast cancer (BC), but the drug resistance keeps an obstructive factor of PTX treatment …

OBJECTIVE: Ovarian cancer (OC) is a common tumor in women, and the development of
chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) …

Increasing evidence has demonstrated the involvement of dysregulated long non-coding
RNAs (lncRNAs) in chemoresistance acting as potential oncogenes or tumor suppressors in …

Acquired resistance to tamoxifen remains a major obstacle in breast cancer (BC) treatment,
since the underlying mechanism has not been fully elucidated. The long non-coding RNA …

Tamoxifen is the gold standard for breast cancer endocrinotherapy. However, drug
resistance remains a major limiting factor of tamoxifen treatment. Long non‑coding (lnc) RNA …

Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances
Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway - PMC …

Background Chemoresistance contributes to treatment failure of gastric cancer (GC) patients
but the molecular mechanism of chemoresistance in GC is still unclear. Long-chain …

Aims Drug resistance is becoming a major clinical challenge to the success of breast cancer
treatment. Compelling evidence has shown the association between the deregulated long …

Background The long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1)
is involved in various cancers and often functions through microRNAs. The pro-survival …

Background: Drug resistance of cancer cells is one of the major causes of chemotherapy
failure. Recently research demonstrated that long non-coding RNA Urothelial cancer …